CA2711878A1 - Therapeutic inhibitors of pai-1 function and methods of their use - Google Patents
Therapeutic inhibitors of pai-1 function and methods of their use Download PDFInfo
- Publication number
- CA2711878A1 CA2711878A1 CA2711878A CA2711878A CA2711878A1 CA 2711878 A1 CA2711878 A1 CA 2711878A1 CA 2711878 A CA2711878 A CA 2711878A CA 2711878 A CA2711878 A CA 2711878A CA 2711878 A1 CA2711878 A1 CA 2711878A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- pai
- peptide
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 84
- 229940124788 therapeutic inhibitor Drugs 0.000 title description 2
- 239000003446 ligand Substances 0.000 abstract description 199
- 108090000623 proteins and genes Proteins 0.000 abstract description 189
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 175
- 230000004807 localization Effects 0.000 abstract description 155
- 102000040430 polynucleotide Human genes 0.000 abstract description 128
- 108091033319 polynucleotide Proteins 0.000 abstract description 128
- 239000002157 polynucleotide Substances 0.000 abstract description 128
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 85
- 229920001184 polypeptide Polymers 0.000 abstract description 73
- 230000000694 effects Effects 0.000 abstract description 45
- 230000001939 inductive effect Effects 0.000 abstract description 38
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 16
- 206010016654 Fibrosis Diseases 0.000 abstract description 10
- 230000004761 fibrosis Effects 0.000 abstract description 10
- 230000002123 temporal effect Effects 0.000 abstract description 10
- PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 290
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 288
- 210000004027 cell Anatomy 0.000 description 140
- 239000013598 vector Substances 0.000 description 127
- 230000014509 gene expression Effects 0.000 description 108
- 230000027455 binding Effects 0.000 description 72
- 125000000539 amino acid group Chemical group 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 70
- 102100035140 Vitronectin Human genes 0.000 description 65
- 150000007523 nucleic acids Chemical class 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 55
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 54
- 238000003780 insertion Methods 0.000 description 53
- 230000037431 insertion Effects 0.000 description 53
- 102000039446 nucleic acids Human genes 0.000 description 43
- 108020004707 nucleic acids Proteins 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 42
- 101800004225 Somatomedin-B Proteins 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 38
- 210000001616 monocyte Anatomy 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 35
- 210000002889 endothelial cell Anatomy 0.000 description 33
- 210000002540 macrophage Anatomy 0.000 description 30
- 108700019146 Transgenes Proteins 0.000 description 28
- 238000000338 in vitro Methods 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 27
- 238000013461 design Methods 0.000 description 26
- 108010031318 Vitronectin Proteins 0.000 description 25
- 230000036961 partial effect Effects 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 24
- 230000037361 pathway Effects 0.000 description 24
- 230000035772 mutation Effects 0.000 description 23
- 230000003480 fibrinolytic effect Effects 0.000 description 22
- 230000009261 transgenic effect Effects 0.000 description 22
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 21
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 239000003527 fibrinolytic agent Substances 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 21
- 238000010200 validation analysis Methods 0.000 description 21
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 20
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 20
- 238000010367 cloning Methods 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000001105 regulatory effect Effects 0.000 description 20
- 229960000187 tissue plasminogen activator Drugs 0.000 description 20
- 238000012546 transfer Methods 0.000 description 20
- 108091023040 Transcription factor Proteins 0.000 description 19
- 102000040945 Transcription factor Human genes 0.000 description 19
- 238000003776 cleavage reaction Methods 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 108020004705 Codon Proteins 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 238000012384 transportation and delivery Methods 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 230000003993 interaction Effects 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 125000006850 spacer group Chemical group 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000007792 addition Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 15
- -1 LEU2 Proteins 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 210000000170 cell membrane Anatomy 0.000 description 13
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 230000003176 fibrotic effect Effects 0.000 description 13
- 108091008146 restriction endonucleases Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 102000012479 Serine Proteases Human genes 0.000 description 12
- 108010022999 Serine Proteases Proteins 0.000 description 12
- 210000004413 cardiac myocyte Anatomy 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000002526 effect on cardiovascular system Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000005003 heart tissue Anatomy 0.000 description 11
- 108020004638 Circular DNA Proteins 0.000 description 10
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 210000002460 smooth muscle Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000024248 Vascular System injury Diseases 0.000 description 9
- 208000012339 Vascular injury Diseases 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 238000001415 gene therapy Methods 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 230000026683 transduction Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 102100038356 Kallikrein-2 Human genes 0.000 description 7
- 101710176220 Kallikrein-2 Proteins 0.000 description 7
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 230000030570 cellular localization Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000001938 Plasminogen Activators Human genes 0.000 description 6
- 108010001014 Plasminogen Activators Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000003143 atherosclerotic effect Effects 0.000 description 6
- 210000001054 cardiac fibroblast Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 229940127126 plasminogen activator Drugs 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102000043279 ADAM17 Human genes 0.000 description 5
- 108091007505 ADAM17 Proteins 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102000000213 Hemojuvelin Human genes 0.000 description 5
- 108050008605 Hemojuvelin Proteins 0.000 description 5
- 101001035447 Humicola insolens Exoglucanase-6A Proteins 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 102000000890 Somatomedin B domains Human genes 0.000 description 5
- 108050007913 Somatomedin B domains Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000009328 Perro Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 108090000333 Transgelin Proteins 0.000 description 4
- 102000003932 Transgelin Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000002557 fixed macrophage Anatomy 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 235000005772 leucine Nutrition 0.000 description 4
- 210000004901 leucine-rich repeat Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000003001 serine protease inhibitor Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000010956 Glypican Human genes 0.000 description 3
- 108050001154 Glypican Proteins 0.000 description 3
- 101001037191 Homo sapiens Hyaluronan synthase 1 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- 229940122055 Serine protease inhibitor Drugs 0.000 description 3
- 101710102218 Serine protease inhibitor Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 241001515826 Cassava vein mosaic virus Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 2
- 102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 2
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 2
- 108050007238 Glypican-1 Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101001077600 Homo sapiens Insulin receptor substrate 2 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 102100024549 Tenascin-X Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 102220351305 c.176C>A Human genes 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000009787 cardiac fibrosis Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 102000021124 collagen binding proteins Human genes 0.000 description 2
- 108091011142 collagen binding proteins Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000003830 regulated secretory pathway Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 102200051510 rs121913152 Human genes 0.000 description 2
- 102220152922 rs755788420 Human genes 0.000 description 2
- 210000000518 sarcolemma Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000004739 secretory vesicle Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 108010020352 tenascin X Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102220557153 Alstrom syndrome protein 1_A56Y_mutation Human genes 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 101100288313 Arabidopsis thaliana KTI4 gene Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 102100031170 CCN family member 3 Human genes 0.000 description 1
- 101710137351 CCN family member 3 Proteins 0.000 description 1
- 101100205088 Caenorhabditis elegans iars-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000701459 Caulimovirus Species 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108020004202 Guanylate Kinase Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 101150030450 IRS1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010091175 Matriptase Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102000011716 Matrix Metalloproteinase 14 Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100055876 Mus musculus Apoe gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 241001467460 Myxogastria Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102100030153 Opalin Human genes 0.000 description 1
- 101710063924 Opalin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 241000701507 Rice tungro bacilliform virus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000004446 Serum Response Factor Human genes 0.000 description 1
- 108010042291 Serum Response Factor Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102220493262 Spermatid nuclear transition protein 1_L43A_mutation Human genes 0.000 description 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150033985 TPI gene Proteins 0.000 description 1
- 101150032817 TPI1 gene Proteins 0.000 description 1
- 102220563539 Tapasin-related protein_T52E_mutation Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 101150058730 Ttpa gene Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000004323 caveolae Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000010365 cell imaging technique Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003918 constitutive secretory pathway Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 101150107963 eno gene Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 102000006638 guanylate kinase Human genes 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 102000056475 human ICAM2 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010083942 mannopine synthase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108700005457 microfibrillar Proteins 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108010015255 protransforming growth factor alpha Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000018477 regulation of fibrinolysis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 102220263973 rs1323126988 Human genes 0.000 description 1
- 102220003317 rs137852699 Human genes 0.000 description 1
- 102200067659 rs397508057 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8132—Plasminogen activator inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01099—Arabinan endo-1,5-alpha-L-arabinosidase (3.2.1.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2013708P | 2008-01-09 | 2008-01-09 | |
| US61/020,137 | 2008-01-09 | ||
| US8064008P | 2008-07-14 | 2008-07-14 | |
| US61/080,640 | 2008-07-14 | ||
| PCT/US2009/000155 WO2009089059A2 (en) | 2008-01-09 | 2009-01-09 | Therapeutic inhibitors of pai-1 function methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2711878A1 true CA2711878A1 (en) | 2009-07-16 |
Family
ID=40853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2711878A Abandoned CA2711878A1 (en) | 2008-01-09 | 2009-01-09 | Therapeutic inhibitors of pai-1 function and methods of their use |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8431363B2 (enExample) |
| EP (1) | EP2242501A4 (enExample) |
| JP (2) | JP2011509093A (enExample) |
| KR (1) | KR101712208B1 (enExample) |
| CN (1) | CN102123721A (enExample) |
| AU (1) | AU2009204464B2 (enExample) |
| BR (1) | BRPI0906867A2 (enExample) |
| CA (1) | CA2711878A1 (enExample) |
| IL (1) | IL206891A0 (enExample) |
| MX (1) | MX2010007586A (enExample) |
| RU (1) | RU2010133847A (enExample) |
| WO (1) | WO2009089059A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8431363B2 (en) | 2008-01-09 | 2013-04-30 | Intrexon Corporation | Polynucleotides encoding therapeutic inhibitors of PAI-1 |
| ES2906750T3 (es) * | 2010-05-12 | 2022-04-20 | Prokidney | Células renales bioactivas |
| CN104271593B (zh) | 2012-05-01 | 2018-01-16 | 富士胶片株式会社 | 多能干细胞的培养方法及该方法中使用的多肽 |
| CN103421781B (zh) * | 2012-07-04 | 2014-12-31 | 华中农业大学 | 猪肌肉组织特异性表达基因myf6启动子及应用 |
| CA2941958A1 (en) * | 2013-12-10 | 2015-06-18 | F. Hoffmann-La Roche Ag | Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure |
| TWI677348B (zh) | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| TWI750189B (zh) * | 2016-12-15 | 2021-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療冠狀動脈粥樣硬化及其併發症的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| JP7604376B2 (ja) | 2018-12-28 | 2024-12-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法 |
| CN119656313B (zh) * | 2024-12-13 | 2026-02-17 | 四川大学华西医院 | Serpine1基因作为靶点在制备预防或治疗心肌纤维化药物中的用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639726A (en) * | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
| CA2385703A1 (en) * | 1999-10-07 | 2001-04-12 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| DE10053251A1 (de) * | 2000-10-26 | 2002-05-08 | Boehringer Ingelheim Pharma | Epitope von PAI-1 |
| US20030211095A1 (en) * | 2002-05-08 | 2003-11-13 | Abd. Al-Roof Higazi | Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy |
| US20030199463A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| JP2006507297A (ja) * | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US7241613B1 (en) * | 2002-06-05 | 2007-07-10 | Oscient Pharmaceuticals Corporation | Identification of Candida cell surface proteins and their uses |
| US20080050808A1 (en) * | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US7785871B2 (en) * | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US7071295B2 (en) * | 2002-12-02 | 2006-07-04 | Intrexon Corporation | Signal for targeting molecules to the sarco(endo)plasmic reticulum |
| WO2004052856A1 (en) | 2002-12-10 | 2004-06-24 | Wyeth | Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| ES2603062T3 (es) | 2004-05-18 | 2017-02-23 | Intrexon Corporation | Métodos de ensamblaje dinámico de vectores para la clonación de ADN de vectores plasmídicos |
| WO2007048103A2 (en) | 2006-10-18 | 2007-04-26 | Intrexon Corporation | Pkd ligands and polynucleotides encoding pkd ligands |
| US8153598B2 (en) * | 2005-10-19 | 2012-04-10 | Intrexon Corporation | PKD ligands and polynucleotides encoding PKD ligands |
| US7943732B2 (en) * | 2006-06-05 | 2011-05-17 | Intrexon Corporation | AKT ligands and polynucleotides encoding AKT ligands |
| US8993263B2 (en) * | 2006-08-07 | 2015-03-31 | Intrexon Corporation | PKA ligands and polynucleotides encoding PKA ligands |
| US8999666B2 (en) * | 2006-08-09 | 2015-04-07 | Intrexon Corporation | PKC ligands and polynucleotides encoding PKC ligands |
| US8729225B2 (en) * | 2006-11-13 | 2014-05-20 | Intrexon Corporation | Glycogen synthase kinase heteropolyligand polypeptide |
| US8283445B2 (en) * | 2006-11-13 | 2012-10-09 | Intrexon Corporation | Extracellular-signal-regulated-kinase (ERK) heteropolyligand polypeptide |
| US7705122B2 (en) * | 2006-12-04 | 2010-04-27 | Intrexon Corporation | mTOR ligands and polynucleotides encoding mTOR ligands |
| ES2390156T3 (es) | 2007-03-27 | 2012-11-07 | Intrexon Corporation | Ligandos de MEK y polinucleótidos que codifican ligandos de MEK |
| EP2150273A4 (en) * | 2007-04-27 | 2010-11-17 | Univ Toledo | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE |
| US8431363B2 (en) | 2008-01-09 | 2013-04-30 | Intrexon Corporation | Polynucleotides encoding therapeutic inhibitors of PAI-1 |
-
2009
- 2009-01-09 US US12/812,127 patent/US8431363B2/en not_active Expired - Fee Related
- 2009-01-09 MX MX2010007586A patent/MX2010007586A/es active IP Right Grant
- 2009-01-09 BR BRPI0906867A patent/BRPI0906867A2/pt not_active IP Right Cessation
- 2009-01-09 CA CA2711878A patent/CA2711878A1/en not_active Abandoned
- 2009-01-09 WO PCT/US2009/000155 patent/WO2009089059A2/en not_active Ceased
- 2009-01-09 RU RU2010133847/10A patent/RU2010133847A/ru not_active Application Discontinuation
- 2009-01-09 AU AU2009204464A patent/AU2009204464B2/en not_active Ceased
- 2009-01-09 KR KR1020107017701A patent/KR101712208B1/ko not_active Expired - Fee Related
- 2009-01-09 EP EP09700772A patent/EP2242501A4/en not_active Withdrawn
- 2009-01-09 CN CN2009801088638A patent/CN102123721A/zh active Pending
- 2009-01-09 JP JP2010542283A patent/JP2011509093A/ja not_active Withdrawn
-
2010
- 2010-07-08 IL IL206891A patent/IL206891A0/en unknown
-
2012
- 2012-01-18 JP JP2012008069A patent/JP2012135307A/ja not_active Withdrawn
-
2013
- 2013-02-15 US US13/769,144 patent/US8828686B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2242501A4 (en) | 2011-10-19 |
| JP2012135307A (ja) | 2012-07-19 |
| EP2242501A2 (en) | 2010-10-27 |
| WO2009089059A3 (en) | 2009-09-24 |
| AU2009204464A1 (en) | 2009-07-16 |
| IL206891A0 (en) | 2010-12-30 |
| US8828686B2 (en) | 2014-09-09 |
| KR20100129271A (ko) | 2010-12-08 |
| US8431363B2 (en) | 2013-04-30 |
| KR101712208B1 (ko) | 2017-03-03 |
| CN102123721A (zh) | 2011-07-13 |
| JP2011509093A (ja) | 2011-03-24 |
| WO2009089059A2 (en) | 2009-07-16 |
| BRPI0906867A2 (pt) | 2019-09-24 |
| MX2010007586A (es) | 2011-02-22 |
| US20130267022A1 (en) | 2013-10-10 |
| AU2009204464B2 (en) | 2014-12-04 |
| US20110055940A1 (en) | 2011-03-03 |
| RU2010133847A (ru) | 2012-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8828686B2 (en) | Polynucleotides encoding therapeutic inhibitors of PAI-1 | |
| KR100188302B1 (ko) | 활성화피브린용해성과항-혈전성단백질 | |
| Nara et al. | Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed “cementoin” | |
| JP4451514B2 (ja) | 血液凝固第ｖｉｉ因子改変体 | |
| JP2022171790A (ja) | 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法 | |
| JP6163304B2 (ja) | 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法 | |
| AU2843900A (en) | Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof | |
| CZ20031718A3 (cs) | Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu | |
| AU2012315516B2 (en) | Compositions and methods for modulating hemostasis | |
| JPH05508664A (ja) | リン脂質標的血栓溶解剤 | |
| Zani et al. | Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases | |
| JP2000509993A (ja) | アポリポタンパク質ｂ―１００由来の抗凝血性ペプチド断片 | |
| US20020077289A1 (en) | Angiostatin and endostatin binding proteins and methods of use | |
| JPH04505554A (ja) | 可溶性トロンボモジュリン類似体 | |
| JP2002524076A (ja) | ＫｕｎｉｔｚドメインポリペプチドＺＫＵＮ６ | |
| CN1798838B (zh) | 一种蛋白酶的抑制剂蛋白及其用途 | |
| KR20190112763A (ko) | 인자 ix 융합 단백질 및 이의 제조 및 사용 방법 | |
| CN105377888A (zh) | 纤维蛋白溶解的双反应性的有效的Kunitz抑制剂 | |
| JP2013517782A (ja) | 因子ｖｉｉ融合ポリペプチド | |
| EP1597360A2 (en) | Antiplasmin cleaving enzyme | |
| CA2924836A1 (en) | Methods and compositions related to mutant kunitz domain i of tfpi-2 | |
| US7223730B2 (en) | Antithrombosis enzyme from the snake venom of agkistrodon acutus | |
| HK40022611A (en) | Antidotes for factor xa inhibitors and methods of using the same | |
| JPH09124700A (ja) | 新規プロテアーゼインヒビターおよびその製造方法、エラスターゼが関与する疾患の治療剤 | |
| JP2003174890A (ja) | 新規セリンプロテアーゼ阻害蛋白質ｍｔ００３９ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131230 |
|
| FZDE | Discontinued |
Effective date: 20190821 |